Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris

This study has been completed.
Facet Biotech
Information provided by:
Rockefeller University Identifier:
First received: December 17, 2002
Last updated: March 12, 2009
Last verified: March 2009
This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris. This is a three-armed study-Daclizumab alone, Cyclosporine alone, and the combination of both Daclizumab and Cyclosporine.

Condition Intervention Phase
Drug: Daclizumab
Drug: Cyclosporine
Drug: cyclosporine and Daclizumab
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Use of Humanized CD25 (Anti-TAC) Monoclonal Antibody and Cyclosporine for the Treatment of Active Psoriasis.

Resource links provided by NLM:

Further study details as provided by Rockefeller University:

Primary Outcome Measures:
  • clinical tolerability of DaclizumabTM and the DaclizumabTM/cyclosporine combination [ Time Frame: day 1, week 1, 2, 3, 4, 5,7,8,9,11, 12, 13, 14 ]

Enrollment: 20
Study Start Date: October 1997
Study Completion Date: April 2008
Primary Completion Date: September 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: cyclosporine
oral medication 2mg/kg/day orally from Day 0 until Day 90
Drug: Cyclosporine
2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
Other Name: Neoral
Active Comparator: anti-TAC
1mg/kg/dose medication every other week on the odd week (week 1-13)
Drug: Daclizumab
1mg/kg medication every other week on the odd week (week 1-13).
Experimental: Cyclosporine and anti-TAC
DaclizumabTM at 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
Drug: cyclosporine and Daclizumab
1mg/kg plus low dose cyclosporine (2 mg/kg/day)

Detailed Description:
The purpose is to study the safety and effectiveness of a new drug called "anti-TAC" (anti-CD25) Monoclonal Antibody used together with low dose Cyclosporine in the treatment of psoriasis. While the exact cause of psoriasis is unknown, it is believed to involve white blood cells called lymphocytes, which become activated in the skin. It is believed that these activated cells are responsible for the changes you see as the rash of psoriasis. Anti-TAC (anti-CD25) Monoclonal Antibody is designed to block the activation of these lymphocytes. Because the anti-TAC (anti-CD25) Monoclonal Antibody targets the specific cells involved in the symptoms of psoriasis, this new drug may be a better way to treat psoriasis. The second drug, Cyclosporine, is an FDA-approved drug in the treatment of psoriasis. There is evidence in the laboratory that Cyclosporine and anti-TAC, used together, will have an additive effect. An additional benefit of this study is that we are using a lower dose of cyclosporine than is usually given when it is used alone because it is being used together with anti-TAC. This should reduce the side effects usually seen with higher doses of Cyclosporine when it is used as a single drug for psoriasis. The purpose of this study is to test the safety and effectiveness of anti-TAC (Monoclonal Antibody and low dose cyclosporine in patients with active, moderate to severe psoriasis vulgaris. We also hope to gain more information on how anti-TAC works in the body

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria

  1. Male or female patients with chronic psoriasis vulgaris (disease stable or worsening for > 6 months). Patients age 16 - 21 will be considered on a case by case basis. Patients below 18 will need parental consent.
  2. Extensive skin involvement.
  3. Scale, thickness, and erythema in individual psoriasis lesions of at least intensity.
  4. Psoriasis treated with emollients only for 2 weeks prior to treatment
  5. Patients with active psoriatic arthritis, if accompanied by psoriasis vulgaris involving more than 5% of the body surface.
  6. History of psoriasis that cannot be treated with topical agents or with previous systemic/ photo(chemo)therapy agents.

Exclusion Criteria:

  1. . Positive serology for HIV, Hepatitis B, or Hepatitis C.
  2. . Positive β-HCG titer. For women of childbearing potential, unwillingness or inability to use a contraceptive device during this study if negative for β-HCG.
  3. Guttate psoriasis, pustular psoriasis, or whole body erythroderma.
  4. Active infection or persistent fever of unknown origin. 5.) Major concurrent illness, which could worsen following treatment with DaclizumabTM.

6) Any history of an un-treated neoplasm

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00050648

United States, New York
Rockefeller University Hospital
New York, New York, United States, 10021
Rockefeller University
New York, New York, United States, 10021
Rockefeller University
New York, New York, United States, 10065
Sponsors and Collaborators
Rockefeller University
Facet Biotech
Principal Investigator: James Krueger, MD, PHD Rockefeller University
  More Information

Responsible Party: James G. Krueger, MD, PhD, Rockefeller University Identifier: NCT00050648     History of Changes
Other Study ID Numbers: JKR-0336
Study First Received: December 17, 2002
Last Updated: March 12, 2009

Keywords provided by Rockefeller University:

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Immunoglobulin G
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors processed this record on April 27, 2017